Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Combination treatment in CTCL: the current role of bexarotene.

Delfino C, Grandi V, Pileri A, Rupoli S, Quaglino P, Alterini R, Goteri G, Canafoglia L, Pimpinelli N.

G Ital Dermatol Venereol. 2012 Dec;147(6):573-80.

PMID:
23149703
2.

The optimal use of bexarotene in cutaneous T-cell lymphoma.

Gniadecki R, Assaf C, Bagot M, Dummer R, Duvic M, Knobler R, Ranki A, Schwandt P, Whittaker S.

Br J Dermatol. 2007 Sep;157(3):433-40. Epub 2007 Jun 6. Review.

PMID:
17553039
3.

Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M.

J Am Acad Dermatol. 2002 Nov;47(5):672-84.

PMID:
12399758
4.

Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.

Kannangara AP, Levitan D, Fleischer AB Jr.

J Dermatolog Treat. 2009;20(3):169-76. doi: 10.1080/09546630802562427.

PMID:
19016373
5.

Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.

Knol AC, Quéreux G, Brocard A, Ballanger F, Khammari A, Nguyen JM, Dréno B.

Exp Dermatol. 2010 Aug;19(8):e95-102. doi: 10.1111/j.1600-0625.2009.00993.x.

6.

Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.

Singh F, Lebwohl MG.

J Am Acad Dermatol. 2004 Oct;51(4):570-3.

PMID:
15389192
7.

Combination treatment modalities in cutaneous T-cell lymphoma (CTCL).

Guitart J.

Semin Oncol. 2006 Feb;33(1 Suppl 3):S17-20. Review.

PMID:
16516671
8.

Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.

Assaf C, Bagot M, Dummer R, Duvic M, Gniadecki R, Knobler R, Ranki A, Schwandt P, Whittaker S.

Br J Dermatol. 2006 Aug;155(2):261-6. Review.

PMID:
16882161
9.

Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.

Väkevä L, Ranki A, Hahtola S.

Acta Derm Venereol. 2012 May;92(3):258-63. doi: 10.2340/00015555-1359.

10.

Optimal combination with PUVA: rationale and clinical trial update.

Stadler R.

Oncology (Williston Park). 2007 Feb;21(2 Suppl 1):29-32. Review.

11.
12.

Management of refractory early-stage cutaneous T-cell lymphoma.

Huber MA, Staib G, Pehamberger H, Scharffetter-Kochanek K.

Am J Clin Dermatol. 2006;7(3):155-69. Review.

PMID:
16734503
13.

Treatment of mycosis fungoides with oral bexarotene combined with PUVA.

Stern DK, Lebwohl M.

J Drugs Dermatol. 2002 Sep;1(2):134-6.

PMID:
12847736
14.

Bexarotene: a clinical review.

Farol LT, Hymes KB.

Expert Rev Anticancer Ther. 2004 Apr;4(2):180-8. Review.

PMID:
15056048
15.

Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.

Pileri A, Delfino C, Grandi V, Pimpinelli N.

Immunotherapy. 2013 Apr;5(4):427-33. doi: 10.2217/imt.13.15. Review.

PMID:
23557425
16.

Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.

Martin AG.

J Drugs Dermatol. 2003 Apr;2(2):155-67. Review.

PMID:
12852367
17.

Topical and oral bexarotene.

Schadt CR.

Dermatol Ther. 2013 Sep-Oct;26(5):400-3. doi: 10.1111/dth.12087.

PMID:
24099070
18.

[Treatment of cutaneous T-cell lymphomas with bexarotene].

Lasa O, Izu R, Acebo E, Eguino P, Díaz-Pérez JL.

Actas Dermosifiliogr. 2005 Dec;96(10):669-73. Spanish. Erratum in: Actas Dermosifiliogr. 2006 Mar;97(2):102.

PMID:
16476317
19.

Treatment of cutaneous T cell lymphoma: current status and future directions.

Apisarnthanarax N, Talpur R, Duvic M.

Am J Clin Dermatol. 2002;3(3):193-215. Review.

PMID:
11978140
20.

Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.

Ballanger F, Nguyen JM, Khammari A, Dréno B.

Dermatology. 2010;220(4):370-5. doi: 10.1159/000305354. Epub 2010 May 13.

PMID:
20484880

Supplemental Content

Support Center